您的位置: 专家智库 > >

国家自然科学基金(30800330)

作品数:2 被引量:2H指数:1
相关作者:张艳雷季良杨立元王君更多>>
相关机构:北京大学更多>>
发文基金:国家自然科学基金北京市自然科学基金国家教育部博士点基金更多>>
相关领域:生物学医药卫生更多>>

文献类型

  • 2篇中文期刊文章

领域

  • 1篇生物学
  • 1篇医药卫生

主题

  • 1篇视网膜
  • 1篇视网膜节
  • 1篇视网膜节细胞
  • 1篇鼠胚
  • 1篇鼠胚胎
  • 1篇胚胎
  • 1篇轴突
  • 1篇组织化学
  • 1篇网膜
  • 1篇细胞
  • 1篇小鼠
  • 1篇小鼠胚胎
  • 1篇吗啡
  • 1篇吗啡耐受
  • 1篇免疫
  • 1篇免疫组织
  • 1篇免疫组织化学
  • 1篇节细胞
  • 1篇阿片
  • 1篇阿片受体

机构

  • 1篇北京大学

作者

  • 1篇王君
  • 1篇杨立元
  • 1篇雷季良
  • 1篇张艳

传媒

  • 1篇解剖学报
  • 1篇Neuros...

年份

  • 1篇2012
  • 1篇2009
2 条 记 录,以下是 1-2
排序方式:
Nogo-A在小鼠胚胎新生视网膜节细胞及其轴突的表达
2009年
目的研究小鼠胚胎阶段Nogo-A在视网膜节细胞(RGCs)及其轴突上的表达及时程变化。方法取不同发育阶段的小鼠胚胎,采用免疫荧光染色,以激光扫描共焦显微镜观察Nogo-A在视觉传导通路中的表达。并采用免疫双标染色确定视网膜中表达Nogo-A蛋白的细胞类型。结果在视网膜发育的早期阶段(E12),Nogo-A密集表达于具有放射状形态的细胞上,Nogo-A免疫阳性产物出现在胞质、胞膜以及轴突上。Nogo-A与Tuj-1双标染色显示,此阶段的视网膜中几乎所有RGCs及其轴突都表达有Nogo-A;在稍晚的发育阶段(E13),视网膜中表达Nogo-A的RGCs数量明显减少,且仅出现在节细胞层以外的室周带和睫状体边缘区。在视网膜的神经纤维层,大部分RGCs轴突不再表达Nogo-A,仅有少量视觉纤维为Nogo-A免疫阳性;RGCs的神经发生基本完成后(E15),视网膜中几乎检测不到Nogo-A免疫阳性的细胞,但视网膜纤维层仍有少量表达Nogo-A的节细胞轴突。与之类似,视神经盘、视茎、视交叉和视束都观察到少量Nogo-A免疫阳性的轴突。值得注意的是,视束中表达Nogo-A的纤维集中位于表浅部位,而此处恰为新近到达轴突的通过部...
王君杨立元张艳雷季良
关键词:NOGO-A视网膜节细胞免疫组织化学小鼠
Disruption of δ-opioid receptor phosphorylation at Threonine 161 attenuates morphine tolerance in rats with CFA-induced inflammatory hypersensitivity被引量:2
2012年
Objective Our previous study identified Threonine 161 (Thr-161), located in the second intracellular loop of the δ-opioid receptor (DOR), as the only consensus phosphorylation site for cyclin-dependent kinase 5 (Cdk5). The aim of this study was to assess the function of DOR phosphorylation by Cdk5 in complete Freund's adjuvant (CFA)-induced inflammatory pain and morphine tolerance. Methods Dorsal root ganglion (DRG) neurons of rats with CFA-induced inflammatory pain were acutely dissociated and the biotinylation method was used to explore the membrane localization of phosphorylated DOR at Thr-161 (pThr-161-DOR), and paw withdrawal latency was measured after intrathecal delivery of drugs orTat-peptide, using a radiant heat stimulator in rats with CFA-induced inflammatory pain. Results Both the total amount and the surface localization of pThr-161-DOR were significantly enhanced in the ipsilateral DRG following CFA injection. Intrathecal delivery of the engineered Tat fusion-interefering peptide corresponding to the second intracellular loop of DOR (Tat-DOR-2L) increased inflammatory hypersensitivity, and inhibited DOR- but not μ-opioid receptor-mediated spinal analgesia in CFA-treated rats. However, intrathecal delivery of Tat-DOR-2L postponed morphine antinociceptive tolerance in rats with CFA-induced inflammatory pain. Conclusion Phosphorylation of DOR at Thr-161 by Cdk5 attenuates hypersensitivity and potentiates morphine tolerance in rats with CFA-induced inflammatory pain, while disruption of the phosphorylation of DOR at Thr-161 attenuates morphine tolerance.
Hai-Jing ChenWei-Yan XieFang HuYing ZhangJun WangYun Wang
关键词:吗啡耐受阿片受体
共1页<1>
聚类工具0